Yuhan Corporation
000100.KS · Bio
Korean pharma with global Leclaza (lazertinib) royalty stream via Johnson & Johnson partnership for EGFR-mutated NSCLC.
Latest news
Yuhan-Kimberly Hosts 11th Forest Nap Contest with Pets
Forest Nap Competition Held in Seoul
Forest Nap Contest Held in Seoul: 'Sleep Is the Best Meditation'
Yuhan-Kimberly Hosts 11th 'Forest Sweet Sleep Contest' in Seoul
Yuhan Wins Korean Phase 1 Approval for MASH Drug Candidate
Yuhan Aims for Tech Transfer Deals on Five Post-Lazcluze Candidates Within Two Years
Korean Drugmakers Reap Rewards from API Plant Expansions
Korean Drugmakers Tap API Business as New Growth Engine
Korean Corporate Disclosures
Yuhan Signs 210.2 Billion Won API Supply Deal with Gilead
Yuhan Eyes Second Straight Year of Operating Profit Above 100 Billion Won on Leclaza
Daiso, Kleannara Launch Ultra-Low-Cost Sanitary Pads at 100 Won Apiece
Korea Top Court Rejects Blanket Tax Exemption for U.S. Subsidiary's Technology Know-How Transfer
Oscotec Q1 Revenue Jumps 88% on Leclaza Milestone Payments
Yuhan Receives 44.8 Billion Won Milestone from Leclaza Europe Commercialization
Korean Drugmakers Soar on Homegrown Blockbusters Alyglo, Leclaza, Cenobamate
Corporate Disclosures
AprilBio Ends Yuhan Research Pact Early to Focus on ADC
Yuhan Corp. Target Price Cut on European Milestone Delay
Korean Drugmakers Eye H2 Pipeline Catalysts After Q1 Earnings
Yuhan Q1 Operating Profit Jumps 37% on Revenue Growth
Yuhan Foundation Awards 'Yoo Il-han Scholarships' to 147 Research Talents